Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q2 | Sep 2, 2025 | Summers Value Fund | -1.8% | -12.8% | ADMA, CCSI, DERM, ELMD, INSP, LGND, OTCM, SPOK, VSTS, ZIMV | Biotech, healthcare, Pharmaceuticals, small caps, underperformance, value | The fund holds multiple pharmaceutical positions including Ligand Pharmaceuticals, ADMA Biologics, and Journey Medical. Healthcare sector sentiment remains weak amid uncertainty from new administration proposals to curb drug pricing and cut Medicare/Medicaid reimbursement. The fund initiated two short positions in pharmaceutical companies where sales expectations are believed to be too high. | DERM DERM |
View |
| 2025 Q2 | Jul 31, 2025 | Minot Light Capital Partners | 18.1% | 4.5% | ACOG, APG, ARQ, CURV, CWAN, CYRX, DERM, LAKE, LGCY, LMB, LQDT, MCW, NEOG, NPKI, OM, REAL, RXST, TDUP, TTGT, XPOF | alpha, dislocations, growth, liquidity, Microcap, small caps, value | The fund focuses exclusively on small and micro-cap companies, targeting market capitalizations well below $100mm and in some cases below $50mm and $25mm. This represents an area where the vast majority of institutional small-cap investors are either unable or unwilling to explore. The strategy seeks to capitalize on inefficiencies in the most illiquid segment of the domestic public equity markets. | CURV RXST TTGT LAKE OM LGCY TDUP OM LGCY TDUP |
View |
| 2025 Q1 | Apr 30, 2025 | Minot Light Capital Partners | -11.5% | -11.5% | CYRX, DAVE, DERM, GRPN, MRVI, OM, REAL, RPID, TDUP, W | Biotechnology, consumer, growth, healthcare, Microcap, small caps, value, volatility | The fund focuses on small and microcap growth stocks with high-beta characteristics. Market corrections provide opportunities to purchase premier growers at reasonable valuations when they become expensive during benign environments. | CYRX |
View |
| 2024 Q4 | Dec 31, 2024 | Minot Light Capital Partners | 5.2% | - | BYON, CFR.SW, DERM, MYTE, REAL, TDUP, TMDX | Dermatology, E-Commerce, growth, Luxury, Microcap, small caps, Specialty Pharma, value | The fund's largest holding MyTheresa operates in the high-end luxury fashion space and recently acquired YOOX NET-A-PORTER from Richemont. The transaction creates substantial synergies and establishes MyTheresa as a leading curated digital platform for luxury fashion. Management expects the combined legacy MYTE and Mr. Porter brands to generate around $2.2 billion in revenues in 2025. | DERM MYTE |
View |
| 2025 Q3 | Nov 8, 2025 | Summers Value Fund | 20.4% | 4.9% | ADMA, CCSI, DERM, ELMD, INSP, LGND, LQDA, QURE, SPOK, SPRY, UFPT, ZIMV | Biotechnology, healthcare, innovation, M&A, Pharmaceuticals, Regulatory, small cap, value | The fund has increased portfolio exposure to biopharma stocks following years of underperformance, believing they are poised for outperformance. The manager is optimistic about the innovation cycle and recognizes that large-cap companies will pay sizeable premiums to acquire attractive pipelines with large sales opportunities. | View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Apr 13, 2026 | Fund Letters | Summers Value Fund | Journey Medical Corporation | Health Care | Pharmaceuticals | Bull | NASDAQ | Commercial Launch, dermatology, FDA approval, patent protection, pharmaceuticals, Revenue Growth, rosacea treatment, Specialty pharma, turnaround | View Pitch |
| Apr 13, 2026 | Fund Letters | Minot Light Capital Partners | Journey Medical | Health Care | Pharmaceuticals | Bull | NASDAQ | Commercial Infrastructure, dermatology, FDA approval, Market Share Gain, product launch, rosacea treatment, Specialty pharma | View Pitch |
| Jan 8, 2026 | Fund Letters | Andrew Summers | Journey Medical Corporation | Health Care | Specialty Pharmaceuticals | Bull | NASDAQ | dermatology, Druglaunch, FDA, growth, pharmaceuticals | View Pitch |
| Sep 1, 2025 | Substack | The 10x Radar | Journey Medical | Healthcare | Drug Manufacturers - Specialty & Generic | Bull | Claude Maraoui, commercial strategy, dermatology, Emrosi, FDA approval, Journey Medical, Medicis, payer coverage, prescription traction, rosacea treatment | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||